Ajer Jeffrey Robert's Form 4 filing
Biomarin Pharmaceutical Inc (BMRN) · filed Jan 27, 2023
- Accession no.
- 0001567619-23-001396
- Filed
- Jan 27, 2023
- Trade date
- Jan 25, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $5.67M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ajer Jeffrey RobertCIK 0001557533 | Officer (EVP, Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 25, 2023 | Common Stock | MOption exerciseAcquired | +49,000 | $67.81 | +$3,322,690 | 90,088 | Direct | |
| Jan 25, 2023 | Common Stock | SSaleDisposed | −44,825 | $115.65F2 | −$5,184,011.25 | 45,263 | Direct | |
| Jan 25, 2023 | Common Stock | SSaleDisposed | −4,175 | $116.15F3 | −$484,926.25 | 41,088 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 25, 2023 | Common Stock | MOption exerciseDisposed | −2,200 | $0.00 | $0 | 0 | Direct | |
| Jan 25, 2023 | Common Stock | MOption exerciseDisposed | −46,800 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price in column 4 is the weighted average price. The price actually received ranged from $115.000 to 115.998. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Referenced by the price of 1 transaction in Table I.
- F3
The price in column 4 is the weighted average price. The price actually received ranged from $116.000 to $116.485. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Referenced by the price of 1 transaction in Table I.